Members of the neuregulin-1 (Nrg1) growth factor family play important roles during Schwann cell development. Recently, it has been shown that the membrane-bound type III isoform is required for Schwann cell myelination. Interestingly, however, Nrg1 type II, a soluble isoform, inhibits the process. The mechanisms underlying these isoform-specific effects are unknown. It is possible that myelination requires juxtacrine Nrg1 signaling provided by the membrane-bound isoform, whereas paracrine stimulation by soluble Nrg1 inhibits the process. To investigate this, we asked whether Nrg1 type III provided in a paracrine manner would promote or inhibit myelination. We found that soluble Nrg1 type III enhanced myelination in Schwann cell-neuron cocultures. It improved myelination of Nrg1 type III ϩ/Ϫ neurons and induced myelination on normally nonmyelinated sympathetic neurons. However, soluble Nrg1 type III failed to induce myelination on Nrg1 type III Ϫ/Ϫ neurons. To our surprise, low concentrations of Nrg1 type II also elicited a similar promyelinating effect. At high doses, however, both type II and III isoforms inhibited myelination and increased c-Jun expression in a manner dependent on Mek/Erk (mitogen-activated protein kinase kinase/extracellular signal-regulated kinase) activation. These results indicate that paracrine Nrg1 signaling provides concentration-dependent bifunctional effects on Schwann cell myelination. Furthermore, our studies suggest that there may be two distinct steps in Schwann cell myelination: an initial phase dependent on juxtacrine Nrg1 signaling and a later phase that can be promoted by paracrine stimulation.
Introduction
Schwann cell development in the peripheral nervous system (PNS) is dependent on contact-mediated signaling between Schwann cells and the associated axons. The neuregulin-1 (Nrg1) and erbB ligand-receptor system lends itself to the task of close contact signaling, as PNS neurons express Nrg1 family ligands and Schwann cells express erbB2 and erbB3, which heterodimerize to form functional Nrg1 receptors (Falls, 2003) .
Members of the Nrg1 family of growth factor are initially expressed on the PNS axons as transmembrane proteins, which are then shed from the membrane by proteolytic processing. All isoforms, types I, II, and III, contain an epidermal growth factor (EGF)-like signaling domain in the extracellular domain that is necessary and sufficient for activating erbB receptors on the Schwann cell surface (Holmes et al., 1992; Lu et al., 1995) . They differ, however, in the sequences N-terminal to the EGF domain; the type I and II isoforms contain an Ig-like domain, whereas type III isoform contains a cysteine-rich domain, which functions as a second transmembrane domain. As a result, Nrg1 type I and II are released and function as paracrine signals after proteolytic cleavage, whereas Nrg1 type III remains tethered to the axonal membrane and mediates juxtacrine signaling (Falls, 2003) .
Recent studies have shown that membrane-bound Nrg1 type III plays an essential role in initiating and regulating myelination in the PNS. Axons that lack Nrg1 type III expression fail to become myelinated (Taveggia et al., 2005) . Overexpression of Nrg1 type III in neurons results in hypermyelination, indicating that the levels of myelination are determined by the amount of Nrg1 type III expressed on individual axons (Michailov et al., 2004; Taveggia et al., 2005) . In contrast, soluble Nrg1 type II has been shown to inhibit Schwann cell myelination and promote dedifferentiation (Zanazzi et al., 2001) . Since both Nrg1 isoforms bind and activate erbB receptors, it is unclear how they elicit opposing effects on myelination. It is possible that juxtacrine signaling provided by the membrane-bound Nrg1 is required for myelination, whereas paracrine signaling by soluble isoforms prevents the process. Alternatively, the isoform-specific effects may be mediated by differential activation of the erbB receptor downstream signaling pathways.
To address the issue, we investigated the effect of Nrg1 type III, presented in a paracrine manner, on Schwann cell myelination. We report that soluble Nrg1 type III elicits a promyelinating function in Schwann cell-neuron cocultures. It increases myelination of Nrg1 type III ϩ/Ϫ neurons but fails to myelinate Nrg1 type III Ϫ/Ϫ neurons. Interestingly, low concentrations of Nrg1 type II also promote myelination, suggesting that the effect is not isoform-specific. At high concentrations, both Nrg1 isoforms inhibit myelination in a manner dependent on Mek/Erk (mitogenactivated protein kinase kinase/extracellular signal-regulated kinase) activation. Altogether, our data suggest that the promyelinating function of Nrg1 is not limited to the juxtacrine signal and can be provided by a paracrine signal in a concentrationdependent manner. Finally, our studies suggest that there may be two distinct steps of Schwann cell myelination: an initial phase dependent on membrane-bound Nrg1 signaling, and a later phase that can be promoted by soluble Nrg1 isoforms.
Materials and Methods
Antibodies. For immunofluorescence analysis, monoclonal antibody (SMI94) to myelin basic protein (MBP) (Covance) was used at 1:300 dilution. For Western blot analysis, monoclonal antibody to phosphoAkt (p-Akt) (Cell Signaling Technology) and polyclonal antibody to phospho-Erk1/2 (Promega) were used at 1:1000 and 1:5000, respectively. Polyclonal antibodies to Akt (Cell Signaling Technology) and Erk1/2 (Promega) were used at 1:1000 and 1:5000, respectively. Polyclonal antibodies to erbB, phospho-erbB2, erbB3, and phospho-erbB3 were used at 1:500 (Santa Cruz Biotechnology). Polyclonal antibody to Krox 20 (Covance) was used at 1:500, polyclonal antibody to MBP (Millipore Bioscience Research Reagents) was used at 1:3000, polyclonal chicken antibody to P0 (Millipore Bioscience Research Reagents) was used at 1:1000, polyclonal antibody to c-Jun (Santa Cruz Biotechnology) was used at 1:400, and monoclonal antibody to ␣-actin (Sigma-Aldrich) was used at 1:5000 dilution.
Type II, type III, and EGF domain neuregulin-1. Recombinant human sensory and motor neuron-derived factor (rhSMDF, type III Nrg1) was purchased from R&D Systems. Recombinant human glial growth factor-II (rhGGF-II, type II Nrg1) was obtained from Acorda Therapeutics under a material transfer agreement. In this study, rhSMDF and rhGGF-II are referred simply as soluble Nrg1 type III and GGF, respectively. The soluble Nrg1 type III was the peptide with N-terminal 296 amino acid residues containing both the EGF domain and cysteine-rich domain (CRD) (Ho et al., 1995) . The GGF was the peptide with N-terminal 519 amino acid residues containing the EGF domain and the Ig-like domain (Marchionni et al., 1993) . Both Nrg1 peptides lacked the transmembrane and cytoplasmic domains. The recombinant human EGF domain fragment of Nrg1 (EGF-Nrg1) was obtained from R&D Systems.
Primary rat Schwann cell culture. Schwann cells were prepared from sciatic nerves of newborn rats (1-2 d old) as described previously (Brockes et al., 1979) . For routine culture, Schwann cells were grown in DMEM (Mediatech) with 10% fetal bovine serum (FBS) (Mediatech) supplemented with 10 ng/ml EGF-Nrg1 and 5 M forskolin (SigmaAldrich). Cells between passages 2 and 4 were used in all experiments described in the text.
In vitro myelination: dorsal root ganglion neuron-Schwann cell cocultures. Dissociated dorsal root ganglion (DRG) was prepared from embryonic day (E) 15.5 rat embryos or E13.5 mouse embryos as described previously (Eldridge et al., 1987) and plated onto type-1 rat tail collagencoated 12 mm glass coverslips at a density of 1.25 DRG/coverslip. Five to six hours later, the cultures were flooded with neurobasal medium (Mediatech) supplemented with B27 (Invitrogen), 0.08% glucose, NGF (50 ng/ml), and a mixture of 15 M 5-fluorodeoxyuridine (FdUr) (SigmaAldrich) and uridine (Sigma-Aldrich). Cultures were maintained in the medium for additional 2-3 d to remove proliferating non-neuronal cells and then switched to fresh medium without FdUr and uridine mixture and maintained until the DRG axons reached the periphery of the coverslips. After the axonal networks were established, Schwann cells were plated onto the neurons at a density of 150,000 cells/coverslip in Minimal Essential Medium (MEM) (Mediatech) supplemented with 10% FBS, 0.08% glucose, and 50 ng/ml NGF. Five to seven days later, cultures were switched to myelinating medium: MEM supplemented with 10% FBS, 0.08% glucose, NGF (50 ng/ml), and ascorbic acid (50 g/ml). Eleven days later, myelination was assessed by immunostaining for MBP. Soluble Nrg1 or U0126 was added at the time of switching to the myelinating medium and replenished every 2 d.
Schwann cell proliferation in cocultures. Bromodeoxyuridine (BrdU; 10 M) was added to the cocultures at the time of the Nrg1 treatment. Sixteen hours later, cultures were fixed in cold methanol and immunostained for BrdU. Briefly, fixed cultures were treated with 2N HCl for 15 min at 37°C. Cells were washed 3 times in 0.1 M borate buffer (pH 8.5) over a 10 min period and then washed 3 times in PBS in the same manner. Cultures were incubated in blocking solution (5% normal goat serum supplemented with 0.2% Triton X-100) for 30 min and incubated with monoclonal BrdU antibody prepared in blocking solution for 1 h at room temperature. Cy2-conjugated goat anti-mouse secondary antibody was added for 1 h and, before mounting, cells were incubated with 4Ј6-diamidino-2-phenylindole⅐2HCl (DAPI) for 1 min to visualize nuclei. Percentage of BrdU-incorporated Schwann cells was determined by counting the number of BrdU-positive nuclei among the DAPI-positive nuclei of the axon-associated Schwann cells.
In vitro myelination: superior cervical ganglion neuron-Schwann cell cocultures. Dissociated superior cervical ganglion (SCG) neurons were prepared from postnatal day 1-2 rats as described previously (Johnson, 2001 ) and plated onto collagen-coated 12 mm glass coverslips at a density of 0.8 SCG/coverslip. Next day, the cultures were flooded with neurobasal medium supplemented with B27, 0.08% glucose, NGF (50 ng/ml), and a mixture of FdUr and uridine (10 M) and maintained in the medium for an additional 2-3 d to remove proliferating non-neuronal cells. The cultures were switched back to fresh medium without FdUr and uridine mixture and maintained until the axons extended out to the periphery of the coverslips. Schwann cells were plated onto the neurons at a density of 200,000 cells/coverslip and maintained in MEM supplemented with 10% FBS, 0.08% glucose, and 50 ng/ml NGF until the Schwann cells populated the axons (ϳ7-10 d). Myelination was initiated by placing the cultures in myelinating medium as described for DRGSchwann cell coculture. Five to six weeks later, myelination was assessed by MBP immunostaining. Soluble Nrg1 was added at the time the cultures were placed in myelinating medium and replenished every 2 d.
Immunofluorescence staining for MBP. DRG-Schwann cell or SCGSchwann cell cocultures were rinsed in PBS and then fixed in 4% paraformaldehyde for 20 min. After washing with PBS, samples were permeabilized in ice-cold methanol for 25 min and then incubated in blocking solution (5% normal goat-serum plus 0.3% Triton X-100) for 1 h at room temperature. This was followed by incubation with MBP primary antibody prepared in blocking solution overnight. After washing with PBS, samples were incubated with Alexa 488-conjugated goat antimouse secondary antibody (Invitrogen) for 45 min. Cell nuclei were stained with DAPI. After mounting, MBP ϩ myelin segments were examined by epifluorescence on a Nikon E800 microscope.
Assessment of myelination (myelin index).
Myelin index was determined as an average fold increase in the number of myelin segments formed in experimental cultures compared with the control cultures. To account for the variability in myelin formation in individual cultures, we established three or four individual coverslips for each experimental condition, and myelin segments, visualized by MBP immunostaining, were counted on all coverslips. For control cultures, pairwise comparisons were made between all coverslips within the group, yielding 9 or 16 ratios per experiment. Ratios from multiple, independent experiments were then averaged and the value was expressed as the myelin index Ϯ SEM for control. A value close to 1 indicates minimal variation in myelination within the control group. For the myelin index in an experimental group, a similar strategy was used to make pairwise comparisons between three or four experimental coverslips and the control coverslips within an experiment. The experimental to control ratios from multiple experiments were then averaged, yielding the myelin index Ϯ SEM for each experimental group.
Measurement of myelin segment length. Following immunostaining for MBP, MBP ϩ myelin segments from 5 to 10 random fields per coverslip were photographed using a 40ϫ objective lens. The digitized images were analyzed using MetaMorph software (MDS Analytical Technology) for measuring lengths of individual myelin segments. A total of 200 -700 individual segments were analyzed from three separate experiments.
Statistical analysis. One-way ANOVA followed by post hoc analysis was performed for all experiments using SigmaStat 3.5 software.
Western blot analysis. To prepare cell lysates, cocultures were washed twice in PBS and then lysed in 300 l of ice-cold lysis buffer (20 mM Figure 1 . Soluble Nrg1 type III promotes Schwann cell myelination. A, Images of myelin segments formed in cocultures treated with soluble Nrg1 type III or GGF at 1 nM. Nrg1 was added at the time of initiating myelination and remained for 11 d, at which time the cultures were fixed and immunostained for MBP and DAPI. Scale bar, 100 m. B, Quantification of myelination in cultures treated with soluble Nrg1 type III at 0.1 and 1 nM. C, Myelination in the presence of GGF (0.3, 0.6, and 1 nM). For B and C, the data were collected from 10 -12 coverslips/condition from three separate experiments. D, Schwann cell proliferation in cocultures. Two hundred thousand Schwann cells were seeded onto dissociated DRG neurons. Three days later, the cocultures were treated with Nrg1 as indicated. Sixteen to eighteen hours later, BrdU was added and 24 h later the cultures were processed for BrdU immunostaining. There was no significant change in Schwann cell proliferation in cultures treated with soluble Nrg1 type III, GGF or EGF-Nrg1 ( p ϭ 0.427). The means Ϯ SEM were determined from five coverslips/condition from two separate experiments. E, Upon initiation of myelination (day 0), cocultures were treated with or without soluble Nrg1 type III (1 nM), and the number of total myelin segments was counted on days 7, 11, and 15. There was a significant increase (*p Ͻ 0.001) in the number of myelin segments in sNrg1 type III-treated cultures compared with the nontreated (NT) control. F, The lengths of individual myelin segments were measured from myelinating cocultures, maintained with or without (NT) sNrg1 type III (1 nM) for 11 d. There was also a significant increase (*p Ͻ 0.001) in the myelin segment length (mean Ϯ SEM, n ϭ 200) in cultures treated with soluble Nrg1 type III at all time points. Tris-HCl, pH 7.4, 1% Nonidet P-40, 10% glycerol, 2.5 mM EGTA, 2.5 mM EDTA, 150 mM NaCl, 20 M leupeptin, 10 g/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride (PMSF), and 1 mM sodium orthovanadate). Lysates were cleared by centrifugation for 15 min at 14,000 rpm in the cold, and the protein concentration of the supernatants was determined. Twenty micrograms of the lysates were size fractionated on 10% SDSpolyacrylamide gel and transferred onto polyvinylidene difluoride membrane. After blocking in 5% milk, the membranes were incubated with appropriate primary antibodies prepared in 5% BSA in TBST (TBS plus 0.05% Tween 20). After incubation with HRP-conjugated secondary antibodies, the protein bands were visualized by enhanced chemiluminescence (ECL).
Results

Soluble Nrg1 type III enhances Schwann cell myelination
To assess the role of soluble Nrg1 type III during myelination, we used a well established in vitro myelinating culture system in which Schwann cells were cocultured with DRG neurons and induced to myelinate by adding ascorbic acid to the culture medium (Eldridge et al., 1987) . As a source of soluble Nrg1 type III, we used the extracellular N-terminal 296 amino acid residues containing the EGF domain and the CRD (Ho et al., 1995) . This recombinant Nrg1 protein has been shown to activate erbB receptors and the downstream signaling pathways in Schwann cells (Taveggia et al., 2005) . Primary rat Schwann cells were seeded onto DRG neurons and allowed to proliferate in association with the axons. At the time of initiating myelination (day 0), cultures were treated and continuously maintained in the presence of the Nrg1 (0.1 or 1 nM). Eleven days later, cultures were fixed and immunostained for MBP to visualize myelin segments. Representative images of the cultures are shown in Figure 1 A. Cultures treated with 1 nM soluble Nrg1 type III (sNrg1 type III) appeared to have a substantial increase in the number of myelin segments compared with nontreated (NT) control cultures. Quantification of the result is shown in Figure 1 B; cultures treated with 1 nM Nrg1 had a 2.9-fold increase in the number of myelin segments over control. In contrast, soluble Nrg1 type II (GGF) (Marchionni et al., 1993) inhibited myelination on DRG neurons in a dose-dependent manner (Fig. 1 A, C) as shown previously (Zanazzi et al., 2001) . The recombinant EGF domain of Nrg1 (EGF-Nrg1) had an effect similar to that of GGF, resulting in a 2.3-fold decrease and an almost complete inhibition of myelination when used at 0.3 and 0.6 nM, respectively (myelin index: NT, 1.28 Ϯ SE 0.31; 0.3 nM EGF domain, 0.56 Ϯ SE 0.09; 0.6 nM EGF domain, 0.005 Ϯ SE 0.003). None of the Nrg1 isoforms had a significant effect on Schwann cell proliferation in cocultures (Fig. 1 D) .
To further analyze the myelinationpromoting effect of soluble Nrg1 type III, we compared the numbers and lengths of myelin segments formed over time during the course of myelination in control and Nrg1-treated cultures. In control cultures, the number of myelin segments increased steadily following the addition of ascorbic acid (day 0) as expected (Fig. 1 E) . In cultures treated with Nrg1 type III, the number increased more rapidly, resulting in a 2.1-, 1.8-, and 2.3-fold increase over the control on days 7, 11 and 15, respectively. There was also a significant increase in the myelin segment length: 86, 107, and 112 m in control cultures versus 116, 142, and 141 m in Nrg1 type III-treated cultures on the corresponding days (Fig.  1 F) . Together, these results suggest that soluble Nrg1 type III elicits a promyelinating function in Schwann cells.
Soluble Nrg1 type III rescues the myelination defect on Nrg1 type III-deficient neurons
Mice deficient in Nrg1 type III expression exhibit defects in Schwann cell myelination. In heterozygous mutant mice, neurons are thinly myelinated and Schwann cells express reduced levels of myelin proteins and promyelinating transcription factors (Michailov et al., 2004; Taveggia et al., 2005 (Fig.  2 A) , confirming the previous in vivo findings (Michailov et al., 2004; Taveggia et al., 2005) . Neurons from Nrg1 type III Ϫ/Ϫ mice failed to myelinate as reported previously (Taveggia et al., 2005) . To determine whether soluble Nrg1 type III could rescue the myelination defects in these neurons, wild-type or mutant cocultures were treated with increasing concentrations of Nrg1 type III (0.1, 0.3, and 1 nM), and myelination was assessed as described above. We found that soluble Nrg1 at 0.3 and 1 nM restored myelination in Nrg1 type III ϩ/Ϫ cultures to wild-type levels (Fig.  2 B) . Representative images are shown in Figure 2C . A similar result was obtained when the number of myelin segments was normalized against the number of Schwann cells, indicating that the improved myelination was not due to an increase in Schwann cell number following Nrg1 treatment (Fig. 2 D) . In addition, there was no obvious cell death in both control and Nrg1-treated cultures (data not shown). Neuregulin also increased the myelin segment length in Nrg1 type III ϩ/Ϫ cultures to the wildtype level (Fig. 2 E) . Soluble Nrg1, however, failed to induce myelination on Nrg1 type III Ϫ/Ϫ neurons at all concentrations tested (data not shown), in agreement with an earlier report (Taveggia et al., 2005 (Fig. 2F ). Membrane-bound Nrg1 type III on the axonal surface is the key Nrg1 isoform that activates the phosphoinositide 3-kinase (PI3-kinase) pathway in associated Schwann cells (Taveggia et al., 2005) . Since activation of PI3-kinase and the effector Akt is crucial for initiating myelination (Maurel and Salzer, 2000; Ogata et al., 2004) , we asked whether Akt activation is decreased in Nrg1 type III ϩ/Ϫ cocultures and subsequently whether soluble Nrg1 type III could increase the activation level. As shown in Figure 2G , under myelinating conditions, the level of active Akt (p-Akt) was substantially decreased in Nrg1 type III ϩ/Ϫ cocultures compared with the wild type. Treatment with soluble Nrg1 type III subsequently increased the p-Akt level. These results indicate that the promyelinating function of soluble Nrg1 type III is associated with an increase in Krox-20 and activation of the key signaling pathway required for myelination.
Soluble Nrg1 type III is sufficient to induce myelination on normally nonmyelinated sympathetic neurons
Small diameter axons, such as those of sympathetic neurons, do not become myelinated but ensheathed due to the low levels of Nrg1 type III expression; forced expression of the type III isoform into these neurons converts them into myelinated ones, highlighting the instructive role of the axonal Nrg1 in determining the myelination state of the PNS neurons (Taveggia et al., 2005) . Therefore, we asked whether soluble Nrg1 type III was sufficient to induce myelination on normally nonmyelinated axons. Sympathetic neurons of the SCG were prepared from postnatal day 2 rats and cocultured with Schwann cells. These neurons expressed lower levels of Nrg1 type III compared with the neurons of DRG (Fig. 3A) , as shown previously (Taveggia et al., 2005) . Once the Schwann cells expanded along the axons, the cultures were maintained under myelinating conditions in the continuous presence of soluble Nrg1 type III (0.1 or 1 nM) for 6 weeks and then fixed and immunostained for MBP. Images and quantification of the cultures are shown in Figure 3B . In control cultures, only a handful of myelin segments were formed despite the lengthy myelination period, which is expected of the low-myelination property of Schwann cells associated with sympathetic neurons. On the contrary, a significant number of myelin segments were formed in cultures treated with the soluble Nrg1. This result indicates that the promyelinating function of soluble Nrg1 is sufficient to induce myelination on normally nonmyelinated small diameter axons.
Inhibition of Mek1/Erk activation blocks the inhibitory function of GGF on myelination
The myelin-promoting effect of soluble Nrg1 type III contrasts with the inhibitory effect of GGF and the EGF-Nrg1 on myelina- , GGF, or sNrg1 type III at 1 nM and cell lysates were prepared at indicated times. Activation states of erbB2 and erbB3 were determined by immunoblotting using activation state-specific antibodies (p-ErbB2, p-ErbB3). All three Nrg1 isoforms show similar receptor activation kinetics for both receptors. B, Activation states of erbB2, Akt, and Erk in Schwann cell-DRG cocultures under myelinating conditions. Cocultures were treated with EGF-Nrg1, GGF, or sNrg1 type III at indicated doses, and 45 min later cell lysates were collected for immunoblotting. Boxed lanes show the states of erbB2, Akt, and Erk activation at 1 nM, a concentration at which EGF-Nrg1 and GGF inhibited myelination while sNrg1 type III promoted myelination, as shown in Figure 1. tion (Fig. 1) . Since we did not observe any noticeable differences in either erbB2 or erbB3 activation kinetics in Schwann cells treated with the neuregulins (Fig. 4 A) , we hypothesized that the isoform-specific effects on myelination might be due to differential activation of the receptor downstream signaling pathways. Previous studies have implicated the Ras/Raf/Erk and PI3 kinase pathways as negative and positive regulators of myelination, respectively, and suggested that the balance between the two may determine the myelination state of the Schwann cells (Maurel and Salzer, 2000; Harrisingh et al., 2004; Ogata et al., 2004) . Therefore, we compared the activation states of the two pathways in cocultures treated with increasing concentrations of EGF-Nrg1, GGF, or soluble Nrg1 type III. Cell lysates were prepared 45 min following the Nrg1 treatment under myelinating conditions, and the presence of the phosphorylated proteins was determined by Western blot analysis (Fig. 4 B) . Activation of erbB2 and Akt appeared at concentrations as low as 0.1 nM with all three Nrg1 isoforms and increased thereafter in a dose-dependent manner. While 0.3 and 0.6 nM EGF-Nrg1 and GGF, respectively, were sufficient to activate Erk, a much higher dose (10 nM) was needed for sNrg1 type III to induce Erk activation. At 1 nM (Fig. 4 B, boxed  lanes) , one of the concentrations tested for myelination in Figure 1 , the inhibitory Nrg1 isoforms (GGF and EGF-Nrg1) activated both Akt and Erk, whereas Nrg1 type III predominantly activated Akt.
To determine whether the Erk activation was associated with the inhibitory effect of GGF, cocultures were treated with GGF along with increasing concentrations of U0126, a specific inhibitor of Erk activator Mek1/2, and maintained under myelinating conditions. Western blot analysis presented in Figure 5A shows that U0126 successfully inhibited GGFinduced Erk activation in a dosagedependent manner while it had no effect on Akt activation (ϩGGF lanes). Next, we assessed the effect of Mek1/2 inhibition on myelination (Fig. 5 B, C) . Addition of U0126 to cocultures reversed the inhibitory effect of GGF, indicated by the dosedependent increase in myelination. This result suggests that Mek1/2 and possibly the downstream effector Erk is likely to mediate the inhibitory effect of GGF on myelination. This result is in agreement with the previous report that growth factor-induced Mek activity inhibits myelin gene expression in Schwann cells (Ogata et al., 2004) . It is also interesting to note that a continuous treatment with U0126 alone, in the absence of GGF, was sufficient to increase myelination (Fig. 5D ). This result suggests that the endogenous Mek/Erk activity in cocultures is likely to work in parallel with GGF to provide an additional negative signal for myelination. Schwann cell-DRG cocultures were pretreated with U0126 for 30 min at indicated doses followed by GGF treatment (0.6 nM). Forty-five minutes later, cell lysates were prepared and the levels of p-Erk and p-Akt were determined. Treatment with U0126 inhibited both endogenous and GGF-induced Erk activation without affecting Akt activation. B, Images of MBP ϩ myelin segments in 11 day myelinating cocultures maintained with GGF alone or in combination with U0126 (1 nM). NT, Nontreated. C, Quantification of myelination in cultures treated with GGF and increasing doses of U0126 (0.5, 1, and 3 M). Treatment with U0126 abolished the inhibitory effect of GGF and increased myelination (*p Ͻ 0.001). The means (ϮSEM) were determined from 10 coverslips per condition from 2 independent experiments. D, In the absence of GGF, cocultures were treated with increasing concentration of U0126 under myelinating conditions, and myelination was analyzed as described above. A significant increase in myelination was observed in cultures treated with U0126 (*p Ͻ 0.001). E, Inhibition of GGF-induced Mek/Erk activation is accompanied by a decrease in c-Jun and an increase in MBP expression. Cocultures were maintained under myelinating conditions in the presence of GGF alone or in combination with U0126 (0.5, 1, and 3 nM) for 11 d, and the cell lysates were analyzed for MBP and c-Jun expression. Levels of actin are shown as loading control.
To determine a possible mechanism by which GGF blocks myelination, we investigated the expression levels of c-Jun, a transcription factor recently described as an inhibitor of Schwann cell differentiation and myelination (Parkinson et al., 2008) . Western blot analysis on lysates prepared from cocultures revealed that GGF treatment increased expression of c-Jun protein (Fig. 5E ). Subsequent treatment with U0126 decreased the c-Jun level in a dose-dependent manner, indicating that the GGFinduced c-Jun expression was dependent on Mek/Erk activity. The decrease in c-Jun was also accompanied by an increase in myelin basic protein expression. These results suggest that the inhibitory effect of GGF on myelination is associated with its induction of c-Jun through the activation of the Mek/Erk pathway.
Soluble Nrg1 type III inhibits myelination at high concentrations in a Mek/Erk-dependent manner
We observed that soluble Nrg1 type III began to activate Erk in the cocultures when used at high concentrations (10 nM) (Fig.  4 B) , suggesting a possibility that it might elicit a negative effect on myelination when the concentration was increased. A series of myelination assays showed that myelination was indeed inhibited in cultures treated with a high-concentration, soluble Nrg1 type III (Fig. 6 A, B) , which was in contrast to the promyelinating function at lower doses demonstrated in Figures 1-3 . As with GGF, the inhibitory effect was dependent on Mek/Erk activation, as cotreatment with U0126 blocked the inhibitory effect and increased myelination. These results suggest that the promyelinating function of soluble Nrg1 type III might not be isoform specific, but rather concentration dependent.
GGF promotes Schwann cell myelination at low concentrations
Next, we investigated whether GGF, previously regarded as the Nrg1 isoform that inhibits myelination, would elicit a similar concentration-dependent dual effects as seen with soluble Nrg1 type III. To address this, we first assessed the concentrationdependent Akt and Erk activation kinetics in cocultures treated with low concentrations of GGF, ranging from 0.0005 to 1 nM. As shown in Figure 7A , Akt activation increased at doses as low as 0.0005 nM, whereas a noticeable increase in Erk activity did not appear until 0.3 nM GGF was used. Consequently, the differential activation of Akt and Erk at the low concentrations generated a narrow range of doses, i.e., between 0.0005 and 0.01 nM, in which Akt was the predominant pathway activated in response to GGF (Fig. 7A, bottom, boxed concentration window) . Myelination assay cocultures showed that within the low concentration range, GGF elicited a promyelinating effect in a dose-dependent manner: 1.5-, 2.3-, 2.2-, and 2.8-fold increase in myelination at 0.0005, 0.001, 0.003, and 0.01 nM GGF, respectively, compared with the control (Fig. 7B) . At higher concentrations GGF inhibited myelination, coinciding with the appearance of Erk activation as shown in Figure 1 . Low doses of GGF were also able to increase myelination on Nrg1 type III ϩ/Ϫ neurons (Fig. 7C) , indicating a direct promyelinating effect similar to that of soluble Nrg1 type III. Altogether, these results show that ectopic stimulation with soluble Nrg1 can both promote and inhibit myelination, and the isoform-independent binary choice is determined by a dose-dependent differential activation of the downstream signaling pathways in Schwann cells.
Discussion
Ectopic stimulation with soluble Nrg1 promotes myelination
Myelination is a complex cellular process that proceeds in several distinct stages. Before initiating myelination, Schwann cells align themselves along the axons and begin the process of radial sorting, adopting a 1:1 relationship with the axons to be myelinated. Concomitantly, Schwann cells become polarized by positioning themselves between the axon and the basal laminae, establishing two distinct membrane domains. This is followed by continuous extension and migration of the inner Schwann cell membrane around the circumference of the axon and, lastly, compaction of the membrane by exclusion of the cytoplasm to the cell periphery.
The membrane-bound Nrg1 type III is a key axonal protein required for myelination in the PNS; however the molecular mechanisms by which it regulates and promotes myelination remain unclear. A recent study has suggested two distinct roles of the axonal Nrg1 during myelination (Taveggia et al., 2005) . In neurons lacking Nrg1 type III expression (Nrg1 type III Ϫ/Ϫ ), Schwann cells do not ensheath or segregate the axons properly and, as a result, fail to myelinate, indicating that the Nrg1 function is essential during the premyelination process. The study has also shown that expression of promyelinating transcription factors in Schwann cells is sensitive to the amount of Nrg1 type III expressed on the associated axons, thus suggesting a direct role of Nrg1 in myelination. By demonstrating that the myelination defect on Nrg1 type III Ϫ/Ϫ neurons could not be rescued by ectopic stimulation with soluble Nrg1, the study further emphasized the importance of the "axonal" Nrg1 in initiating myelination.
Therefore, an intriguing finding of the present study is the rescue of the myelination defect in Nrg1 type III ϩ/Ϫ cultures by soluble Nrg1 (Figs. 1, 2 Taveggia et al., 2005) . Addition of soluble Nrg1, as shown in this study, then increases expression levels of Krox20 and myelin proteins, leading to enhanced myelination. These data suggest that soluble Nrg1 elicits a promyelinating function, independent of the previous sorting process, that is likely to require membrane-bound axonal Nrg1 type III. This notion is further supported by the finding that soluble Nrg1 also promotes myelination on axons of normally nonmyelinated SCG neurons (Fig. 3) that express low levels of Nrg1 type III (Taveggia et al., 2005) but are properly ensheathed and segregated by the associated Schwann cells.
Axonal Nrg1 type III is required for the early events of myelination
The rescue of myelination by soluble Nrg1 of Nrg1 type III ϩ/Ϫ but not Nrg1 type III Ϫ/Ϫ neurons implies the exclusive requirement of juxtacrine Nrg1 signaling during early events of axonal segregation and ensheathment. The mechanism by which membrane-bound Nrg1 regulates early axon-Schwann cell interaction remains unknown. It is possible that activation of Nrg1-erbB receptor signaling at the Schwann cell-axon interface is important for establishing the initial polarity before myelination. In polarized epithelial cells, domain-specific activation of erbB2 regulates differentiation phenotype (Ramsauer et al., 2006) . It is also possible that Nrg1-erbB cooperates with other cell surface receptors or adhesion molecules that function at the axon-glial interface. Neurotrophin receptor p75 is required for myelination and is localized to the adaxonal domain through its interaction with polarity protein Par-3 (Chan et al., 2006) . Several cell adhesion molecules, including cadherins and nectin-like proteins, have also been shown to mediate axon-Schwann cell interaction at this junction and are required for myelination (Wanner et al., 2006; Maurel et al., 2007; Spiegel et al., 2007) . Whether the erbB receptor complex interacts with these proteins at the junction or whether the interaction has a functional significance during early events of myelination remains unknown. It is also possible that the spatial opposition between the Nrg1-erbB and the basal lamina-integrin signal at the abaxonal junction is required for the premyelination process (Benninger et al., 2007; Nodari et al., 2007) .
Soluble Nrg1 can both promote and inhibit myelination: a binary choice determined by the concentration In the PNS, GGF has been regarded as the Nrg1 isoform associated with the Schwann cell injury response that inhibits myelination (Huijbregts et al., 2003) . Thus, an unexpected result of this study was the myelination-promoting effect of GGF when used at low concentrations. A similar observation was made with sNrg1 type III, which at high concentrations inhibited myelination, while at low doses promoted the process. This is an intriguing finding, as it demonstrates that independently of the isoforms, soluble Nrg1 can elicit two contrasting biological functions under the same cellular context based solely on the amount presented to the cell. This can be explained by a concentrationdependent differential activation of the receptor downstream signaling effectors in Schwann cells shown by all three Nrg1 isoforms; our data show that the promyelinating function of Nrg1 is observed at concentrations that preferentially activate Akt, while the transition into the inhibitory role at higher concentrations coincides with the appearance of Erk activation. Consequently, inhibition of the Nrg1-induced Erk activity reverses the inhibitory effect on myelination. These results support the previous notion that the overall balance between PI3-kinase and Ras/Raf/Erk activation determines the myelination state of Schwann cells (Ogata et al., 2004) . Alternatively, it is also possible that Nrg1 might have an indirect effect on the signaling events that occur in neurons through the associated Schwann cells, thus regulating myelination (Esper and Loeb, 2004) . In the CNS, while Nrg1 type III function is not required for initiating myelination, its ectopic expression in CNS neurons nevertheless enhances myelination (Brinkmann et al., 2008) . Soluble Nrg1 also promotes myelination in oligodendrocyte progenitor cell-DRG cocultures; however, it does not exhibit an inhibitory effect on oligodendrocyte myelination (Wang et al., 2007) . This suggests differences in the mechanisms by which myelination is regulated in oligodendrocytes and Schwann cells.
The inhibitory function of Nrg1 on myelination is likely to be mediated through activation of the Mek/Erk pathway The Ras/Raf/Erk pathway plays an inhibitory role during Schwann cell differentiation by blocking myelin gene expression (Harrisingh et al., 2004; Ogata et al., 2004) . However, its direct role during myelination has not been elucidated. Here, we show that treatment with Mek1/2 inhibitor blocks the inhibitory role of ectopic soluble Nrg1 and restores myelination, suggesting that the inhibitory role of Nrg1 is likely to be mediated through its activation of the Mek/Erk pathway. The mechanism by which Mek/Erk activation inhibits myelination is unclear. A possible mechanism includes suppression of myelin gene expression as described above. Supporting this, our data show that Mek1/2 inhibition increases MBP expression in GGF-treated cultures (Fig. 4) . It is also possible that the Mek/Erk pathway regulates the expression of transcription factors involved in Schwann cell differentiation and myelination. Recently, it has been shown that c-Jun functions as a negative regulator of the myelination program in the PNS (Parkinson et al., 2008) . Accordingly, we find that the inhibitory effect of GGF is accompanied by an increase in c-Jun expression, which is suppressed when Mek is inhibited. This, therefore, suggests that the Mek/Erk function on myelination is in part mediated through induction of c-Jun.
Another interesting finding of the present study is the presence of an intrinsic Mek/Erk-dependent signal that serves as a negative regulator of myelination. This was shown in experiments in which treatment of normal myelinating cocultures with the Mek inhibitor promoted myelination. The nature of the signal that contributes to the Mek/Erk activity during myelination is presently unknown, although it is likely to be axonal in origin, independent of the axonal Nrg1 type III (Taveggia et al., 2005) . Several Mek/Erk activators, such as FGF-2 and PDGF, are expressed on PNS neurons and their receptors are found on Schwann cells (Hardy et al., 1992; Eccleston et al., 1993; Oellig et al., 1995; Grothe and Wewetzer, 1996) . Treatment with FGF-2 downregulates myelin gene expression and inhibits myelination in vitro (Zanazzi et al., 2001 ). It will be of great interest to assess the regulatory roles of these growth factors during myelination in the PNS.
Therapeutic potential of soluble Nrg1
The rebuilding of myelin in demyelinated lesions in the nervous system by transplanting exogenous myelin-forming glial cells is a concept that has been explored and tested for many years. Schwann cells offer the possibility of autologous transplantation, as they are easily obtained and expanded in culture and myelinate when transplanted in demyelinated lesions (Duncan et al., 1981 ; Baron-Van Evercooren et al., 1992; Morrissey et al., 1995) . However Schwann cell remyelination of adult axons is often incomplete, resulting in the formation of thinner myelin sheathes and shorter internodes compared with normal nerves (Beuche and Friede, 1985; Kohama et al., 2001; Lankford et al., 2002) . The promyelinating effect of soluble Nrg1 presented in this study is significant, as it provides a potential therapeutic strategy for improving myelination by Schwann cells. However, it should be cautioned that concentrations above the threshold level could have a devastating consequence on the pathologic condition. Further understanding of the inhibitory role of Ras/Raf/Erk pathway on myelination might provide insights into developing a combined strategy for improving myelination.
